SCWorx Soars 77% on Heavy Volume Amid Q2 Filing and Major Stake Disclosures

Introduction

SCWorx Corp (ticker: WORX) is a Nasdaq-listed provider of supply chain interoperability solutions for the healthcare sector. Utilizing software-as-a-service (SaaS) and cloud technologies, the company offers materials management and data analytics tools designed to normalize supply-related data across clinical, financial, and operational systems. SCWorx’s Ultraverse Platform employs machine learning and artificial intelligence to support an integrated suite of modules that assist hospitals and health systems in managing costs, negotiating contracts, and enhancing clinical outcomes.

Corporate Structure

Headquartered in the United States, SCWorx employs between 11 and 50 professionals. Leadership includes:

• Timothy A. Hannibal, President and Chief Executive Officer since January 2019, with nearly 30 years in SaaS, cloud technology, and mergers and acquisitions, including founding VaultLogix, which was acquired by J2 Global.
• Christopher J. Kohler, Chief Financial Officer, founder of Kohler Consulting, Inc., with over 15 years of experience in finance and accounting for private and public companies.

The company’s Korean name is 에스씨웍스.

Supply Chain by CHUTTERSNAP

Developments and News

Metric	Value
Stock Price (08/25/2025)	$0.5151
Change (%)	+77.13
Volume	19,265,012
Exchange	NAS

• On August 14, 2025, SCWorx filed its quarterly report on Form 10-Q (Acc-no: 0001213900-25-076369) with the U.S. Securities and Exchange Commission.
• The same day, the company submitted Amendment No. 2 to its Schedule 13G, disclosing that Iroquois Capital Management, LLC holds 305,524 shares (7.75%) and Richard Abbe controls 403,850 shares (9.99%), with beneficial ownership blockers of 4.99% and 9.99%, respectively.
• On May 15, 2025, SCWorx filed the previous quarter’s Form 10-Q (Acc-no: 0001213900-25-044293).

Financial and Strategic Analysis

SCWorx’s SaaS solution has been associated with helping healthcare providers manage medical expenses, revenues, and patient safety by providing real-time information that aids in purchasing and vendor negotiations. The Ultraverse Platform underpins these functions with a virtualized item data warehouse (VDW) that integrates across solution modules. While specific revenue and profitability figures were not disclosed in public filings, the 77.13% increase in share price on August 25, 2025, and the elevated trading volume indicate increased investor interest, which may correlate with the Schedule 13G amendments and the anticipation of quarterly results.

Strategic initiatives include continued investment in machine learning and AI for data normalization, expansion of module functionality, and potential partnerships to broaden market reach. Capital-raising instruments such as convertible notes and warrants, mentioned in investor filings, may support these growth efforts.

Market Position and Industry Context

SCWorx operates in the hospital supply chain market, a segment focusing on data interoperability, cost management, and contract administration. Its Materials Management Information System (MMIS) serves as a single source of truth for supply-related data, addressing the industry's demand for integrated platforms that unify supply chain, finance, and clinical workflows. As regulatory requirements and competitive pressures necessitate integrated analytics, SCWorx’s Ultraverse Platform positions the company among providers of specialized SaaS solutions for healthcare organizations.

TL;DR

• Shares increased 77.13% to $0.5151, with 19.3 million shares traded on August 25, 2025.
• On August 14, 2025, SCWorx filed its Q2 Form 10-Q and amended Schedule 13G, revealing key investors holding stakes of up to 9.99%.
• The Ultraverse Platform, supported by AI and machine learning, is central to SCWorx’s strategy for enhancing supply chain interoperability.
• Upcoming catalysts include Q3 earnings, further adoption of SaaS modules, and developments related to convertible notes and warrants.